MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD
15 Apr 2024
Phase 3Phase 2Microbial therapyClinical Result
Preview
Source: FierceBiotech
MaaT Pharma drilled down into a subset of 49 patients who more closely match those in an ongoing phase 3 trial of MaaT013.
A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the microbiome biotech has touted 18-month data as proof it’s on track to launch the drug in acute graft-versus-host disease (aGvHD) in two years’ time.
The 18-month data are taken from 140 patients with either steroid-refractory or steroid-dependent gastrointestinal aGvHD who received the therapy, dubbed MaaT013, as part of the French biotech’s Pharma Early Access Program. Among these heavily pretreated patients, the data showed a “clear overall survival advantage,” with a 54% rate of overall survival at six months, 47% at 12 months and 42% at 18 months.
Overall survival was “significantly higher” in patients who responded to MaaT013 compared to non-responders at 18 months—at 58% versus 24%, respectively—the company noted.
The biotech also drilled down into a subset of 49 patients whose disease had proven resistant to treatment by both steroids and Incyte’s Jakafi. Among these patients—who more closely match those in an ongoing phase 3 trial of MaaT013—the gastrointestinal overall response rate was higher, at 63%, than the 52% across the whole group. Overall survival at 18 months remained at 42% among this subset.
“The confirmation of an improvement in 18-month survival, compared to the data already presented, by the company, at 12 months, reinforces our confidence in the ongoing development, notably the results of the current phase 3 trial,” MaaT’s CEO Hervé Affagard said in a statement.
“Beyond the significant impact for patients, this advancement distinguishes our treatment in a context where current options offer only limited benefits and lead to severe complications,” Affagard added. “Anticipating a positive phase 3 outcome and a potential commercial launch in 2026, we aim to capture a substantial share of the market for third-line patients, thereby marking a turning point in the management of this condition.”
MaaT has seen combining stool samples from multiple donors as a way to improve the diversity and standardization of MaaT013. But the practice proved to be a sticking point in the U.S., where the FDA imposed a 20-month hold on moving the drug into a phase 3 for aGvHD that was only lifted in April 2023.
As well as the phase 3 study of MaaT013 in aGvHD, the biotech is also testing the therapy for metastatic melanoma in a phase 2 study in combination with immune checkpoint inhibitors.
The company’s other clinical-stage asset is MaaT033, another so-called “microbiome ecosystem therapy” that is in a phase 1 trial for amyotrophic lateral sclerosis and a phase 2 study for improving survival among blood cancer patients who have received a bone marrow transplant.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.